The global Research Antibodies Market is estimated to be valued at US$ 3785.5 Bn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Research antibodies are proteins produced by the immune system to defend the body against foreign substances, called antigens. Antibodies play a key role as crucial tools in biological research and medical diagnostic applications. They recognize and bind specifically to the antigen they were raised against. Recombinant antibodies have produced more consistently and effectively, driving their adoption in research activities.
Market key trends:
One of the key trends in the research antibodies market is the rising adoption of recombinant antibodies. Recombinant antibodies have many advantages over traditional production methods such as hybridoma technology. Recombinant antibodies can be quickly and cost-effectively manufactured by inserting gene sequences that encode the antibody into host cells. The host cells then produce the antibody in large quantities with consistent quality. This makes them an affordable and readily available option for research compared to hybridoma-produced antibodies. Furthermore, recombinant antibodies have human-like sequences making them less immunogenic and suitable for therapeutic applications. Their consistent production and reduced immunogenicity propel the growth of recombinant antibodies segment.
The global research antibodies market is segmented on the basis of product, technology, application, end-user and geography. By product, the market is classified into primary antibodies and secondary antibodies. The primary antibodies segment is expected to dominate the market during the forecast period. This is due to the wide application of primary antibodies across various research areas such as proteomics, genomics and drug discovery.
Global Research Antibodies Market Size is expected to witness high growth, exhibiting a CAGR of 5.9% over the forecast period, due to increasing research activities in the field of proteomics, genomics and drug development.
North America is expected to dominate the research antibodies market during the forecast period. This is attributed to the high funding for research activities from private and public organizations in the region. Asia Pacific is anticipated to grow at the fastest rate fueled by increasing investments by governments and market players in the countries such as China and India.
Key players operating in the research antibodies market are Thermo Fisher Scientific Inc, Bio-rad Laboratories, Lonza Group, Merck Millipore, Cell Signalling Technology Inc., F.Hoffmann La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company, Agilent Technologies, Danaher Corporation, BioLegend Inc., Illumina, Phoenix Pharmaceuticals, Abcam plc. Thermo Fisher Scientific Inc is expected to maintain its dominance in the market owing to its broad product portfolio and global presence.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it